Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment
Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment
復旦-張江生物製藥公司在美國進行的第二階段試驗中首位患者入組，用於治療胎記。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間